Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study is a research paper published in Journal of Cystic Fibrosis (2020). On theSindex it has a DataRank of 0. It has been cited 41 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Cystic Fibrosis Foundation Therapeutics
Grant: SAGEL14K1
Cystic Fibrosis Foundation Therapeutics
Grant: HAMBLE14K1
Cystic Fibrosis Foundation Therapeutics
Grant: ROWE19R0
National Institutes of Health
Grant: R35HL135816
National Institutes of Health
Grant: DK089507
National Institutes of Health
Grant: P30DK072482
National Institutes of Health
Grant: UL1 TR002535
NIDDK NIH HHS
Grant: P30 DK089507
National Institutes of Health
Cystic Fibrosis Trust
MeSH Terms
Additional file 1 of The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world setting
Additional file 1 of The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world setting